CLINICAL TRIALS AND OBSERVATIONS Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
نویسندگان
چکیده
Michele Baccarani,1 Gianantonio Rosti,1 Fausto Castagnetti,1 Ibrahim Haznedaroglu,2 Kimmo Porkka,3 Elisabetta Abruzzese,4 Giuliana Alimena,5 Hans Ehrencrona,6 Henrik Hjorth-Hansen,7 Veli Kairisto,8 Luciano Levato,9 Giovanni Martinelli,1 Arnon Nagler,10 Johan Lanng Nielsen,11 Ugur Ozbek,12 Francesca Palandri,1 Fausto Palmieri,13 Fabrizio Pane,14 Giovanna Rege-Cambrin,15 Domenico Russo,16 Giorgina Specchia,17 Nicoletta Testoni,1 Ole Weiss-Bjerrum,18 Giuseppe Saglio,15 and Bengt Simonsson6
منابع مشابه
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Result of high-dose imatinib mesylate in patients with Philadelphia chromosome–positive chronic myeloid leukemia after failure of interferon-
Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. We investigated whether higher doses of imatinib may be more effective. Thirty-six patients with chronicphase CML after failure on interferonwere treated with 400 mg imatinib twice daily. Median time from diagnosis was 25 mon...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase
In chronic myelogenous leukemia (CML) imatinib mesylate has been shown to selectively inhibit the tyrosine kinase domain of the oncogenic bcr-abl fusion protein. Using this agent alone high rates of cytogenetic responses were recorded. However, several mechanisms of resistance have been described. In vitro studies examining the effects of imatinib mesylate plus cytarabine have shown synergistic...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
We assessed the long-term efficacy of imatinib dose escalation in 84 patients with chronic myeloid leukemia in chronic phase who met the criteria of failure to standard-dose imatinib. Twenty-one patients with hematologic failure and 63 with cytogenetic failure had their imatinib dose escalated from 400 to 800 mg daily (n 72) or from 300 to 600 mg daily (n 12). After a median follow-up of 61 mon...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
Patients not in complete cytogenetic response (CCyR) continuously face the competing possibilities of eventually achieving a cytogenetic response versus progressing. We analyzed the probability of achieving a CCyR, major molecular response, and progression in 258 patients with chronic myeloid leukemia in early chronic phase at 3, 6, and 12 months from imatinib start. The initial imatinib dose w...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoid leukemias
The translocation (9;22) gives rise to the p190Bcr-Abl and p210Bcr-Abl tyrosine kinase proteins, considered sufficient for leukemic transformation. Philadelphia-positive (Ph ) acute leukemia patients failing to respond to initial induction therapy have a poor prognosis with few effective treatment options. Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase. We c...
متن کامل